Keywords : Levetiracetam
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 6, Pages 889-896
Epilepsy is a disease related to central nervous system disorder where brain activity become unusual, thereby a patient experience a seizures or periods of strange behaviour, vibrations, and sometimes loss of consciousness. It might be due to genetic disorder or some sort of brain injury, such as shock or stroke. It requires a long duration treatment of drug therapy for getting cured. As per various researches half of patients do not pass the initial antiepileptic treatment and around 35 per cent are highly resistant to medical treatment, demonstrating the rising requirement for more effectual and improved tolerated medicines. Levetiracetam is an adjunctive management of seizures in victims with epilepsy, the fourth most general neurological chaos distressing individuals of different age groups. Its pharmacokinetic compensation comprise fast and approximately full absorption, limited irrelevant binding with plasma protein, no activation of enzymes, no connections with other products, and unfair metabolism external the liver.Yet another advantage is the provision of an intravenous injection. This has been shown to be efficient as adjunctive treatment for partial-onset refractory seizures, primary widespread tonic-conic seizures, and juvenile myoclonic seizure. In addition, controlled release of carbamazepine was found to be similar to first-line treatment for partial-onset seizure, together in effectiveness and acceptability.